Tesofensine
Weight Loss / CNS Compound (Triple Reuptake Inhibitor)investigationalAlso known as: NS2330, TE
A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's disease, repurposed as a potent weight-loss agent.
Overview
Tesofensine is a small-molecule triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine. Originally developed by NeuroSearch for neurodegenerative diseases (Parkinson's and Alzheimer's), it was unexpectedly found to produce significant weight loss in clinical trials — patients lost substantially more weight than with any approved anti-obesity drug at the time. This led to its repurposing as an anti-obesity compound. In a Phase II trial, tesofensine 0.5mg produced an average weight loss of 12.8 kg over 24 weeks, far exceeding results seen with sibutramine or other available agents. It reduces appetite through central appetite suppression and increases resting energy expenditure via sympathetic activation. While technically not a peptide, tesofensine is commonly included in peptide clinic weight-loss protocols. It is currently in Phase III trials in several countries and has regulatory approval in some markets (Mexico as Tesomet in combination with metoprolol).
Mechanism of Action
Tesofensine acts on central monoamine systems: (1) Inhibits reuptake of serotonin (5-HT), reducing appetite and increasing satiety signaling; (2) Inhibits norepinephrine reuptake, increasing sympathetic tone and resting energy expenditure; (3) Inhibits dopamine reuptake, enhancing reward signaling and reducing food-seeking behavior; (4) Increases thermogenesis through elevated catecholamine activity; (5) Reduces overall caloric intake by 26-32% without formal dietary restriction; (6) Has a long half-life (~9 days) allowing once-daily dosing.
Molecular Formula
C17H23NO3
Molecular Weight
289.37 g/mol
Sequence
N/A — small molecule, not a peptide
Dosage Protocols
Dose Range
0.25mg – 0.5mg
Frequency
Once daily
Route
oral
Cycle Length
12-24 weeks
Start at 0.25mg and titrate to 0.5mg after 1-2 weeks. Take in the morning to avoid sleep disruption. 1.0mg was tested but caused unacceptable cardiovascular effects. Long half-life (~9 days) means steady state takes weeks. Often combined with beta-blocker (metoprolol) to mitigate heart rate increase.
Source: Phase II clinical trial protocols
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
0.5mg tablets, 30ct
Last Updated
2026-02
Triple monoamine reuptake inhibitor. Oral tablet. Available from telehealth clinics: $150-300/mo. Strong appetite suppression. Not FDA-approved.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Increased heart rate | moderate |
| Dry mouth | mild |
| Insomnia | mild |
| Constipation | mild |
| Elevated blood pressure | moderate |
| Mood changes | moderate |
Pros & Cons
Produced the largest weight loss of any drug in Phase II trials at the time — 12.8 kg average in 24 weeks
Oral administration with once-daily dosing due to long half-life
Dual mechanism: reduces appetite AND increases energy expenditure
Potential cognitive/mood benefits from dopamine reuptake inhibition
Cardiovascular side effects (heart rate, blood pressure) require monitoring and possible beta-blocker co-therapy
Not yet FDA-approved — limited availability in most countries
CNS-active compound with potential for mood changes and sleep disruption
Long half-life means side effects persist for days if they occur
Research Studies
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
Not FDA-approved. Phase III clinical trials ongoing. Approved in Mexico as part of Tesomet (tesofensine + metoprolol). Available from some compounding pharmacies and research chemical suppliers. Prescription-only where approved.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.